Paxlovid Access In Austria: Availability And Eligibility

Paxlovid is an antiviral medication for the treatment of COVID-19. It is a combination of two drugs, nirmatrelvir and ritonavir, which work together to inhibit viral replication and prevent the spread of the virus. The treatment is most effective when taken within five days of the onset of symptoms and is approved for use in people aged 12 years and older, weighing at least 88 pounds, who have tested positive for the virus. While Paxlovid is available in Austria, there have been mixed reports of travellers successfully obtaining it. In general, a prescription from a doctor is required, and it may be challenging to obtain Paxlovid without an Austrian prescription.

Paxlovid is available in Austria with a prescription

To obtain Paxlovid in Austria, you must first test positive for Covid-19. Then, you will need to see a doctor, who will decide whether Paxlovid treatment is necessary based on your symptoms, severity, risks, and any relevant government and health authority directives. If the doctor decides Paxlovid is appropriate for your situation, they will provide a prescription.

With a prescription, Paxlovid can be collected from pharmacies throughout Austria. In some cases, you may be able to call your general practitioner to obtain the prescription, without needing an in-person consultation.

It is important to start Paxlovid treatment as soon as possible after testing positive, as it is most effective when taken within five days of symptom onset. If you are a traveller in Austria, it may be useful to research local clinics and pharmacies in advance, so you know where to go if you need to.

It's approved for adults at risk of severe COVID-19

Paxlovid is available in Austria and has been since March 2022. The drug is approved for use in adults at risk of severe COVID-19. This includes people with previous illnesses, the elderly, or those who have not been vaccinated. It is not a substitute for vaccination but can be used as a treatment to reduce the risk of hospitalisation or death.

Paxlovid is a combination of two drugs: nirmatrelvir and ritonavir. Nirmatrelvir works by blocking the action of a certain protein that the virus needs to replicate and spread. Ritonavir slows the breakdown of nirmatrelvir, allowing it to stay in the body longer and continue to prevent replication of the virus. The treatment must be started as soon as possible after a confirmed infection and within five days of the onset of symptoms. The full course of treatment is twelve doses taken over five days, with each dose consisting of two nirmatrelvir tablets and one ritonavir tablet.

In Austria, Paxlovid can be prescribed by registered doctors and collected from pharmacies throughout the country. It is also available through the Test-to-Treat program, which provides Paxlovid free of charge to patients with COVID-19 symptoms who test positive at a participating pharmacy.

While Paxlovid is a promising treatment option for those at risk of severe disease, it is not a preventive medication. It is meant to be used as a treatment for people who have tested positive for COVID-19 and are at high risk of progression to severe illness. Clinical trials are underway to study its potential as a preventive medication.

Paxlovid is a combination of two drugs

Paxlovid is available in Austria, with the Austrian Ministry of Health signing a contract with Pfizer in February 2022 to make the drug available from mid-March onwards.

Nirmatrelvir

Nirmatrelvir works by blocking the action of a protein that the virus needs to replicate and spread throughout the body. By reducing the amount of virus in the body, nirmatrelvir may also lower the chance of passing the disease to others. Each dose of Paxlovid consists of two 150-mg tablets of nirmatrelvir.

Ritonavir

Ritonavir works to slow down the breakdown of nirmatrelvir in the body, allowing it to stay in the body longer and continue to prevent the replication of the virus. Each dose of Paxlovid contains one 100-mg tablet of ritonavir.

Paxlovid is taken as two doses per day, twelve hours apart, for five days. It is important to start the medication as soon as possible after a positive COVID-19 test, within five days of the onset of symptoms.

Paxlovid is approved for use in people aged 12 and older who weigh at least 88 pounds and have tested positive for COVID-19. It is not authorised as a preventive medication, either before or after exposure to COVID-19. However, clinical trials are underway to study these potential uses.

It's not a substitute for vaccination

Paxlovid is available in Austria and can be accessed by tourists. However, it is not a substitute for vaccination. While Paxlovid is a promising treatment for COVID-19, it is not a preventive medication. It is intended to treat COVID-19 in high-risk individuals who have already contracted the virus and are at risk of severe illness or hospitalization. Vaccination, on the other hand, is a preventive measure that helps protect individuals from contracting COVID-19 in the first place.

The Austrian Ministry of Health has emphasized that Paxlovid is not a substitute for vaccination. Vaccination remains the primary tool for preventing COVID-19 infections and reducing the burden on the healthcare system. While Paxlovid can help reduce the severity of the disease and prevent hospitalizations, it is not as effective as vaccination in providing protection against COVID-19.

Furthermore, Paxlovid is not authorized as a preventive medication, either before or after exposure to COVID-19. It is meant to be taken within five days of the onset of symptoms, and its effectiveness decreases if treatment is delayed. Vaccination, on the other hand, provides ongoing protection against the virus, reducing the likelihood of infection and severe illness.

In addition, the availability of Paxlovid may vary, and it may not be accessible to everyone who needs it. Vaccination, on the other hand, is widely available and easily accessible to the majority of the population. Vaccines can be administered through various channels, such as local clinics, pharmacies, and vaccination centers, making it convenient for individuals to get vaccinated.

Moreover, Paxlovid is not suitable for everyone. It is intended for high-risk individuals, such as those with previous illnesses, the elderly, or those who have not been vaccinated. Vaccination, however, is generally safe and recommended for most people, providing protection against COVID-19 regardless of their risk factors. Vaccination also helps reduce the strain on healthcare resources, as it reduces the number of hospitalizations and severe cases.

In conclusion, while Paxlovid is a valuable treatment option for COVID-19, it should not be considered a substitute for vaccination. Vaccination remains the most effective way to prevent COVID-19 infections, reduce the risk of severe illness, and alleviate the burden on the healthcare system. Paxlovid should be used as a supplementary treatment option for those who are at high risk of severe illness, in conjunction with vaccination to provide the best protection against COVID-19.

Paxlovid is available in all Austrian pharmacies

Paxlovid is available in Austria, and it can be accessed in Austrian pharmacies with a prescription. However, it is not a substitute for vaccination and is intended only for high-risk patients.

In March 2022, Austria received tens of thousands of doses of Paxlovid, with further tranche deliveries planned throughout the year. The drug is a combination of two tablets, nirmatrelvir and ritonavir, which work together to inhibit viral replication and prevent the multiplication of the coronavirus in the body's cells. The treatment must be started as soon as possible after a confirmed infection and within five days of symptom onset.

In Austria, Paxlovid can be prescribed by registered doctors in the case of a Covid-19 infection. A phone call to a general practitioner is usually sufficient to obtain a prescription. The drug can then be collected directly from any pharmacy throughout the country.

It is important to note that Paxlovid is not a substitute for vaccination against Covid-19. The Austrian Ministry of Health has emphasized that while Paxlovid provides an additional treatment option, vaccination remains essential in the fight against the virus.

Additionally, Paxlovid is intended only for high-risk patients. This includes individuals with specific previous illnesses, the elderly, those who are unvaccinated, or those with other risk factors such as obesity or compromised immune systems. If you fall into a high-risk category, it is recommended that you contact your doctor immediately if you test positive for Covid-19.

Frequently asked questions